Prostate Cancer - Episode 3

Episode 3 - Radium-223 for the Treatment of CRPC

In addition to cytotoxic chemotherapy, immunotherapy, and oral agents that target the androgen pathway, David Crawford, MD, discusses radium-223 as a therapeutic option for the treatment of castration-resistant prostate cancer (CRPC).

Dr Crawford cites the ALSYMPCA clinical trial and explains how the trial tested radium-223 and found that the drug demonstrated several benefits to patients with CRPC. Benefits included increased survival rates, decreased instances of overall pain, and lower numbers of symptomatic skeletal events and fractures, as well as lessened the need for treatment with surgery or radiation.